<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054803</url>
  </required_header>
  <id_info>
    <org_study_id>BST-SCI-02</org_study_id>
    <nct_id>NCT05054803</nct_id>
  </id_info>
  <brief_title>Cell Therapy for Chronic Traumatic Cervical Incomplete Spinal Cord Injury</brief_title>
  <official_title>A Phase I/II, Randomized, Double-blind, Placebo-controlled, Parallel, 2-arms Clinical Trial to Assess the Safety and Efficacy of Intrathecal Administration of WJ-MSC in Chronic Traumatic Cervical Incomplete Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banc de Sang i Teixits</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Guttmann</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academic Research Organization (ARO) - VHIR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Banc de Sang i Teixits</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, multicenter clinical trial in which&#xD;
      18 patients affected with chronic traumatic incomplete cervical spinal cord injury will be&#xD;
      randomized to either the active treatment (2 doses of intrathecal WJ-MSC 3 months apart) or&#xD;
      to placebo (2 intrathecal infusions, 3 months apart). Thereafter, patients will be&#xD;
      followed-up for 12 months for safety and efficacy assessment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind, randomized, placebo-controlled, multicenter clinical trial that will include 18&#xD;
      patients affected with chronic traumatic incomplete cervical spinal cord injury who will be&#xD;
      randomized 2:1, stratified by center, to one of the 2 treatment arms of the study: WJ-MSC /&#xD;
      WJ-MSC (at a dose of 1E6 ± 30% live cells / Kg of weight) or Placebo / placebo. Medication&#xD;
      will be administered intrathecally at day 1 and at 3 months. The main objective of the trial&#xD;
      is to assess safety at 12-month follow-up. Secondary objectives include the evaluation of&#xD;
      efficacy through clinical response, electrophysiological changes, questionnaires of&#xD;
      functionality and quality of life, as well as the presence of anti-HLA antibodies and donor&#xD;
      cellularity in the cerebrospinal fluid.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, randomized, placebo-controlled, 2-arms, multicenter clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Active treatment and placebo will be released using the same syringe and blinded in a way that it is no possible to distinguish one to the other.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessment</measure>
    <time_frame>At 12 month follow-up</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ASIA punctuation</measure>
    <time_frame>At 1, 3, 4, 6 and 12 month follow-up</time_frame>
    <description>Changes in ASIA score with respect to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor evoked potentials</measure>
    <time_frame>At 6 and 12 month follow-up</time_frame>
    <description>Changes in motor evoked potentials score with respect to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Somatosensory evoked potentials</measure>
    <time_frame>At 6 and 12 month follow-up</time_frame>
    <description>Changes in somatosensory evoked potentials score with respect to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical pain threshold perception</measure>
    <time_frame>At 6 and 12 month follow-up</time_frame>
    <description>Changes in electrical pain threshold perception score with respect to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip Strength</measure>
    <time_frame>At 6 and 12 month follow-up</time_frame>
    <description>Will be assessed using a dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walk test WISCIII</measure>
    <time_frame>At 6 and 12 month follow-up</time_frame>
    <description>Changes in the walk test WISCIII score with respect to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical scale for neuropathic pain assessment</measure>
    <time_frame>At 6 and 12 month follow-up</time_frame>
    <description>Changes in the numerical scale for neuropathic pain score with respect to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Ashworth scale for spasticity</measure>
    <time_frame>At 6 and 12 month follow-up</time_frame>
    <description>Changes in the modified Ashworth scale score with respect to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCIM III scale for functionality</measure>
    <time_frame>At 6 and 12 month follow-up</time_frame>
    <description>Changes in the SCIM III scale score with respect to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire (WHOQOL-BREF)</measure>
    <time_frame>At 6 and 12 month follow-up</time_frame>
    <description>Changes in the WHOQOL-BREF score with respect to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological general well-being index (PGWBI)</measure>
    <time_frame>At 12 month follow-up</time_frame>
    <description>Changes in the PGWBI score with respect to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>At 12 month follow-up</time_frame>
    <description>Changes in the HADS score with respect to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Community Integration Questionaire (CIQ-IG)</measure>
    <time_frame>At 12 month follow-up</time_frame>
    <description>Changes in the CIQ-IG score with respect to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AntiHLA antibodies in cerebrospinal fluid (CSF)</measure>
    <time_frame>At 7 days and at 1 month follow-up after each infusion</time_frame>
    <description>Presence or absence of antiHLA antibodies in the CSF after two WJ-MSC infusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of donor cells in CSF</measure>
    <time_frame>At 7 days after each infusion</time_frame>
    <description>Short tandem repeat (STR) analysis to detect permanence of donor cellularity (WJ-MsC) in the CSF</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Spinal Cord Injury Cervical</condition>
  <arm_group>
    <arm_group_label>WJ-MSC (XCEL-UMC-BETA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-filled syringe with 4 ± 1 mL containing WJ-MSC in a balanced saline solution supplemented with human albumin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pre-filled syringe with 4 ± 1 mL containing a balanced saline solution supplemented with human albumin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WJ-MSC (XCEL-UMC-BETA)</intervention_name>
    <description>Administration of 2 Intrathecal infusions of WJ-MSC at day 1 and at 3 months</description>
    <arm_group_label>WJ-MSC (XCEL-UMC-BETA)</arm_group_label>
    <other_name>Tested product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of 2 Intrathecal infusions of placebo at day 1 and at 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Single spinal cord injury lesion caused by trauma&#xD;
&#xD;
          2. Affected cord segments between C1 and T1, confirmed by magnetic resonance&#xD;
&#xD;
          3. Incomplete lesion (ASIA B, C or D)&#xD;
&#xD;
          4. Chronic disease state (between 1 and 5 years after the injury)&#xD;
&#xD;
          5. Patients from 18 to 70 years of age, both sexes&#xD;
&#xD;
          6. Life expectancy &gt; 2 years&#xD;
&#xD;
          7. Residence near the center during study participation and confidence that the patient&#xD;
             will attend the follow-up visits&#xD;
&#xD;
          8. Given informed consent in writing&#xD;
&#xD;
          9. Patient is able to understand the study and its procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mechanic ventilation&#xD;
&#xD;
          2. Penetrating trauma affecting the spinal cord&#xD;
&#xD;
          3. Pregnant woman or without proper anticonceptive measures according to the&#xD;
             investigator, or breath feeding&#xD;
&#xD;
          4. Planned spinal surgery within subsequent 12 month after entering the trial&#xD;
&#xD;
          5. Neurodegenerative diseases&#xD;
&#xD;
          6. Significant abnormal laboratory tests that contraindicates patient's participation in&#xD;
             the study&#xD;
&#xD;
          7. Neoplasia within the previous 5 years, or without complete remission&#xD;
&#xD;
          8. Patient with communication difficulties&#xD;
&#xD;
          9. Simultaneous participation in another clinical trial or treated with an&#xD;
             investigational medicinal product the previous 30 days, that could interfere in the&#xD;
             results of the study&#xD;
&#xD;
         10. Previous treatment with and advanced Therapy Medicinal Product (cell therapy)&#xD;
&#xD;
         11. Contraindication for lumbar punction&#xD;
&#xD;
         12. Contraindication or inability to follow a rehabilitation program&#xD;
&#xD;
         13. Other pathologic conditions or circumstances that difficult participation in the study&#xD;
             according to medical criteria&#xD;
&#xD;
         14. The patient does not accept to be followed-up for a period that could exceed the&#xD;
             clinical trial length&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan VIDAL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Guttmann</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruth COLL, MD</last_name>
    <phone>+34935573500</phone>
    <phone_ext>6707</phone_ext>
    <email>rucoll@bst.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joaquin DELGADILLO, MD, PhD</last_name>
    <phone>+34935573500</phone>
    <phone_ext>6643</phone_ext>
    <email>jadelgadillo@bst.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Neurorehabilitació Institut Guttmann</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Joan Vidal, MD, PhD</last_name>
      <phone>+34 934977700</phone>
      <email>jvidal@guttmann.com</email>
    </contact>
    <contact_backup>
      <last_name>Jesús Benito, MD, PhD</last_name>
      <phone>+34 934977700</phone>
      <email>jbenito@guttmann.com</email>
    </contact_backup>
    <investigator>
      <last_name>Joan Vidal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesús Benito, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hatice Kumru Cam, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario A Coruña (CHUAC)</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Antonio Montoto, MD, PhD</last_name>
      <phone>+34 981 178117</phone>
      <email>antonio.montoto.marques@sergas.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://www.bancsang.net</url>
    <description>Blood and tissue bank of Catalonia, cell producer and sponsor of the trial</description>
  </link>
  <link>
    <url>https://www.guttmann.com/</url>
    <description>Hospital specialized in spinal cord injury</description>
  </link>
  <link>
    <url>https://xxicoruna.sergas.gal/Paxinas/web.aspx?tipo=paxtxt&amp;idContido=595&amp;idLista=4</url>
    <description>Hospital specialized in spinal cord injury</description>
  </link>
  <reference>
    <citation>Albu S, Kumru H, Coll R, Vives J, Vallés M, Benito-Penalva J, Rodríguez L, Codinach M, Hernández J, Navarro X, Vidal J. Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy. 2021 Feb;23(2):146-156. doi: 10.1016/j.jcyt.2020.08.008. Epub 2020 Sep 25.</citation>
    <PMID>32981857</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spinal cord injury</keyword>
  <keyword>Mesenchymal stromal cells</keyword>
  <keyword>Wharton jelly</keyword>
  <keyword>Cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

